-
1تقرير
المؤلفون: Braun, M. C., Decker, T., Hegemann, N., Kerstan, S. F., Maier, C., Ulmanis, J.
مصطلحات موضوعية: Quantum Physics
الوصف: We present a method to model a discretized time evolution of probabilistic networks on gate-based quantum computers. We consider networks of nodes, where each node can be in one of two states: good or failed. In each time step, probabilities are assigned for each node to fail (switch from good to failed) or to recover (switch from failed to good). Furthermore, probabilities are assigned for failing nodes to trigger the failure of other, good nodes. Our method can evaluate arbitrary network topologies for any number of time steps. We can therefore model events such as cascaded failure and avalanche effects which are inherent to financial networks, payment and supply chain networks, power grids, telecommunication networks and others. Using quantum amplitude estimation techniques, we are able to estimate the probability of any configuration for any set of nodes over time. This allows us, for example, to determine the probability of the first node to be in the good state after the last time step, without the necessity to track intermediate states. We present the results of a low-depth quantum amplitude estimation on a simulator with a realistic noise model. We also present the results for running this example on the AQT quantum computer system PINE. Finally, we introduce an error model that allows us to improve the results from the simulator and from the experiments on the PINE system.
الوصول الحر: http://arxiv.org/abs/2303.16588Test
-
2تقرير
المؤلفون: Braun, M. C., Decker, T., Hegemann, N., Kerstan, S. F., Lorenz, F.
مصطلحات موضوعية: Quantum Physics
الوصف: We present a method to formulate the unit commitment problem in energy production as quadratic unconstrained binary optimization (QUBO) problem, which can be solved by classical algorithms and quantum computers. We suggest a first approach to consider uncertainties in the renewable energy supply, power demand and machine failures. We show how to find cost-saving solutions of the UCP under these uncertainties on quantum computers. We also conduct a study with different problem sizes and we compare results of simulated annealing with results from quantum annealing machines.
الوصول الحر: http://arxiv.org/abs/2301.01108Test
-
3تقرير
المؤلفون: Braun, M. C., Decker, T., Hegemann, N., Kerstan, S. F.
مصطلحات موضوعية: Quantum Physics
الوصف: We show how phase and amplitude estimation algorithms can be parallelized. This can reduce the gate depth of the quantum circuits to that of a single Grover operator with a small overhead. Further, we show that for quantum amplitude estimation, the parallelization can lead to vast improvements in resilience against quantum errors. The resilience is not caused by the lower gate depth, but by the structure of the algorithm. Even in cases with errors that make it impossible to read out the exact or approximate solutions from conventional amplitude estimation, our parallel approach provided the correct solution with high probability. The results on error resilience hold for the standard version and for low depth versions of quantum amplitude estimation. Methods presented are subject of a patent application [Quantum computing device: Patent application EP 21207022.1].
الوصول الحر: http://arxiv.org/abs/2204.01337Test
-
4دورية أكاديمية
المؤلفون: Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Koerber, Stefan Alexander, Debus, Jürgen, Peeken, Jan C., Vogel, Marco M. E., Kroeze, Stephanie G. C., Guckenberger, Matthias, Krafcsik, Manuel, Hruby, George, Emmett, Louise, Schmidt-Hegemann, N.-S., Trapp, Christian, Spohn, Simon, Henkenberens, Christoph, Mayer, Benjamin, Shelan, Mohamed, Aebersold, Daniel Matthias, Thamm, Reinhard, Wiegel, Thomas
المصدر: Radiotherapy and oncology. - 194 (2024) , 110215, ISSN: 1879-0887
الوصف: Purpose The European Association of Urology (EAU) proposed a risk stratification (high vs. low risk) for patients with biochemical recurrence (BR) following radical prostatectomy (RP). Here we investigated whether this stratification accurately predicts outcome, particularly in patients staged with PSMA-PET. Methods For this study, we used a retrospective database including 1222 PSMA-PET-staged prostate cancer patients who were treated with salvage radiotherapy (SRT) for BR, at 11 centers in 5 countries. Patients with lymph node metastases (pN1 or cN1) or unclear EAU risk group were excluded. The remaining cohort comprised 526 patients, including 132 low-risk and 394 high-risk patients. Results The median follow-up time after SRT was 31.0 months. The 3-year biochemical progression-free survival (BPFS) was 85.7 % in EAU low-risk versus 69.4 % in high-risk patients (p = 0.002). The 3-year metastasis-free survival (MFS) was 94.4 % in low-risk versus 87.6 % in high-risk patients (p = 0.005). The 3-year overall survival (OS) was 99.0 % in low-risk versus 99.6 % in high-risk patients (p = 0.925). In multivariate analysis, EAU risk group remained a statistically significant predictor of BPFS (p = 0.003, HR 2.022, 95 % CI 1.262–3.239) and MFS (p = 0.013, HR 2.986, 95 % CI 1.262–7.058). Conclusion Our data support the EAU risk group definition. EAU risk grouping for BCR reliably predicted outcome in patients staged lymph node-negative after RP and with PSMA-PET before SRT. To our knowledge, this is the first study validating the EAU risk grouping in patients treated with PSMA-PET-planned SRT.
وصف الملف: pdf
الإتاحة: https://doi.org/10.1016/j.radonc.2024.110215Test
https://freidok.uni-freiburg.de/data/246374Test
https://nbn-resolving.org/urn:nbn:de:bsz:25-freidok-2463740Test
https://freidok.uni-freiburg.de/dnb/download/246374Test -
5دورية أكاديمية
المؤلفون: Koerber, Stefan Alexander, Höcht, Stefan, Aebersold, Daniel Matthias, Albrecht, Clemens, Boehmer, Dirk H.G., Ganswindt, Ute, Schmidt-Hegemann, N.-S., Hölscher, Tobias, Mueller, A.-C., Niehoff, Peter, Peeken, Jan Caspar, Pinkawa, Michael, Polat, Bülent, Spohn, Simon, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, Wiegel, Thomas
المصدر: Strahlentherapie und Onkologie. - 200 (2024) , 181–187, ISSN: 1439-099X
الوصف: For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.
وصف الملف: pdf
الإتاحة: https://doi.org/10.1007/s00066-023-02193-4Test
https://freidok.uni-freiburg.de/data/243982Test
https://nbn-resolving.org/urn:nbn:de:bsz:25-freidok-2439827Test
https://freidok.uni-freiburg.de/dnb/download/243982Test -
6دورية أكاديمية
المؤلفون: Koerber, S A, Höcht, S, Aebersold, Daniel, Albrecht, C, Boehmer, D, Ganswindt, U, Schmidt-Hegemann, N-S, Hölscher, T, Mueller, A-C, Niehoff, P, Peeken, J C, Pinkawa, M, Polat, B, Spohn, S K B, Wolf, F, Zamboglou, C, Zips, D, Wiegel, T
المصدر: Koerber, S A; Höcht, S; Aebersold, Daniel; Albrecht, C; Boehmer, D; Ganswindt, U; Schmidt-Hegemann, N-S; Hölscher, T; Mueller, A-C; Niehoff, P; Peeken, J C; Pinkawa, M; Polat, B; Spohn, S K B; Wolf, F; Zamboglou, C; Zips, D; Wiegel, T (2024). Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO). Strahlentherapie und Onkologie, 200(3), pp. 181-187. Springer 10.1007/s00066-023-02193-4
مصطلحات موضوعية: 610 Medicine & health
الوصف: For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.
وصف الملف: application/pdf
العلاقة: https://boris.unibe.ch/192147Test/
-
7تقرير
المؤلفون: Braun, M. C., Decker, T., Hegemann, N., Kerstan, S. F., Schäfer, C.
مصطلحات موضوعية: Quantum Physics
الوصف: We present a novel use case for quantum computation: the sensitivity analysis for a risk model used at Deutsche B\"orse Group. Such an analysis is computationally too expensive to perform on classical computers. We show in detail how the risk model and its analysis can be implemented as a quantum circuit. We test small scale versions of the model in simulation and find that the expected quadratic speedup compared to the classical implementation used at Deutsche B\"orse Group can be realized. Full scale production usage would be possible with less than 200 error corrected qubits. Our quantum algorithm introduces unitary but imperfect oracles which use Quantum Amplitude Estimation to detect and mark states. This construction should be of general interest and we present theoretical results regarding the performance of Grover's search algorithm with imperfect oracles.
الوصول الحر: http://arxiv.org/abs/2103.05475Test
-
8دورية أكاديمية
المؤلفون: Spohn, Simon K.B., Draulans, C., Kishan, A.U., Spratt, Daniel E., Ross, A., Maurer, T., Tilki, Derya, Berlin, Alejandro, Blanchard, Pierre, Collins, S., Bronsert, P., Chen, Ronald C., Pra, A.D., de Meerleer, G., Eade, Thomas, Haustermans, K., Hölscher, T., Höcht, S., Ghadjar, Pirus, Davicioni, E., Heck, M., Kerkmeijer, Linda G.W., Kirste, Simon, Tselis, N., Tran, Phuoc T., Pinkawa, M., Pommier, P., Deltas, Constantinos D., Schmidt-Hegemann, N.-S., Wiegel, T., Zilli, Thomas, Tree, A.C., Qiu, X., Murthy, V., Epstein, Jonathan I., Graztke, Christian, Gao, Xin, Grosu, A.L., Kamran, Sophia C., Zamboglou, C.
المساهمون: University of Freiburg Freiburg, Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven), University of California Los Angeles (UCLA), University of California (UC), Case Western Reserve University Cleveland, Feinberg School of Medicine, Northwestern University Evanston, University Hospital Hamburg-Eppendorf, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf Hamburg (UKE), University of Toronto, Institut Gustave Roussy (IGR), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University of Kansas Kansas City, University of Miami, Royal North Shore Hospital (RNSH), Technische Universität Dresden = Dresden University of Technology (TU Dresden), Charité - UniversitätsMedizin = Charité - University Hospital Berlin, Veracyte SAS, Technische Universität Munchen - Technical University Munich - Université Technique de Munich (TUM), Radboud University Medical Center Nijmegen, Johann Wolfgang Goethe University Hospital, University of Maryland Baltimore, MediClin Robert-Janker-Klinik Bonn, Centre Léon Bérard Lyon, University of Cyprus Nicosia (UCY), Ludwig-Maximilians University Hospital (LMU Munich), Universitätsklinikum Ulm - University Hospital of Ulm, Geneva University Hospital (HUG), The institute of cancer research London, Nanjing University (NJU), Tata Memorial Centre, Johns Hopkins University School of Medicine Baltimore, Massachusetts General Hospital Boston, Harvard Medical School Boston (HMS), European University of Cyprus, W81XWH-22-1-0044, U.S. Department of Defense, DOD: RSD1836, Prostate Cancer Foundation, PCF, Radiological Society of North America, RSNA, Jonsson Comprehensive Cancer Center, JCCC, National Institute for Health and Care Research, NIHR, Cancer Research UK, CRUK: C33589/A28284, C7224/A28724 CRUK RadNet, Institute of Cancer Research, ICR, Deutsche Forschungsgemeinschaft, DFG, Bundesministerium für Bildung und Forschung, BMBF: Med-Call/JTC2019-299 01KU2015, Klaus Tschira Stiftung, KTS, This study is supported by the German Federal Ministry of Education and Research (BMBF) as part of the ERA PER Joint Funding Call 2019 (grant no. Med-Call/JTC2019-299 01KU2015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Acknowledgments—A.T. acknowledges support from Cancer Research UK (C33589/A28284 and C7224/A28724 CRUK RadNet). This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We thank Fotini Miltiadous for administrative support., Disclosures: A.U.K. reports funding support from grant P50CA09213 from the Prostate Cancer National Institutes of Health Specialized Programs of Research Excellence and grant W81XWH-22-1-0044 from the Department of Defense, as well as grant RSD1836 from the Radiologic Society of North America, the STOP Cancer organization, the Jonsson Comprehensive Cancer Center, and the Prostate Cancer Foundation. C.Z. received funding from the Klaus Tschira foundation, Naslund Medical, and from the German Research Foundation. C.Z. received speaker fees from Johnson & Johnson and Novocure, all outside the submitted work. E.D. is an employee of Veracyte, manufacturer of Decipher. A.R. is a consultant and/or speaker for Astellas, Bayer, Pfizer, Blue Earth, Lantheus, Janssen, Tempus, and Veracyte. X.G. is on the consulting/advisory board for Bayer, Myovant, and Guardant Health.
المصدر: ISSN: 0360-3016.
مصطلحات موضوعية: [SDV]Life Sciences [q-bio]
الوصف: International audience ; Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ≥75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and systemic therapy. The ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36596346; hal-04122783; https://hal.science/hal-04122783Test; https://hal.science/hal-04122783/documentTest; https://hal.science/hal-04122783/file/2023_Blanchard_IntJRadiatOncolBiolPhys.pdfTest; PUBMED: 36596346
الإتاحة: https://doi.org/10.1016/j.ijrobp.2022.12.038Test
https://hal.science/hal-04122783Test
https://hal.science/hal-04122783/documentTest
https://hal.science/hal-04122783/file/2023_Blanchard_IntJRadiatOncolBiolPhys.pdfTest -
9دورية أكاديمية
المؤلفون: Solomonidou N., Germanou D., Strouthos I., Karagiannis E., Farolfi A., Koerber S. A., Debus J., Peeken J. C., Vogel M. E., Vrachimis A., Spohn S. K. B., Shelan M., Aebersold D., Grosu A. -L., Ceci F., Kroeze S. G. C., Guckenberger M., Fanti S., Belka C., Hruby G., Scharl S., Wiegel T., Bartenstein P., Henkenberens C., Emmett L., Schmidt-Hegemann N. S., Ferentinos K., Zamboglou C.
المساهمون: Solomonidou N., Germanou D., Strouthos I., Karagiannis E., Farolfi A., Koerber S.A., Debus J., Peeken J.C., Vogel M.E., Vrachimis A., Spohn S.K.B., Shelan M., Aebersold D., Grosu A.-L., Ceci F., Kroeze S.G.C., Guckenberger M., Fanti S., Belka C., Hruby G., Scharl S., Wiegel T., Bartenstein P., Henkenberens C., Emmett L., Schmidt-Hegemann N.S., Ferentinos K., Zamboglou C.
مصطلحات موضوعية: Prostate cancer, Prostate-specific antigen, PSMA-PET, Salvage radiotherapy
الوصف: Purpose: The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2ng/ml. Methods: The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed. Results: The final cohort consisted of 273 patients; 78/273 (28.6%) and 48/273 (17.6%) patients had local or nodal recurrence on PET/CT. The most frequently applied sRT dose to the prostatic fossa was 66–70Gy (n = 143/273, 52.4%). SRT to pelvic lymphatics was delivered in 87/273 (31.9%) patients and androgen deprivation therapy was given to 36/273 (13.2%) patients. After a median follow-up time of 31.1months (IQR: 20–44), 60/273 (22%) patients had biochemical recurrence. The 2- and 3-year BRFS was 90.1% and 79.2%, respectively. The presence of seminal vesicle invasion in surgery (p = 0.019) and local recurrences in PET/CT (p = 0.039) had a significant impact on BR in multivariate analysis. In 16 patients, information on recurrence patterns on PSMA-PET/CT after sRT was available and one had recurrent disease inside the RT field. Conclusion: This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field.
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36905411; volume:50; issue:8; firstpage:2529; lastpage:2536; numberofpages:8; journal:EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; https://hdl.handle.net/11585/957717Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85149771795; https://link.springer.com/article/10.1007/s00259-023-06185-5Test
-
10دورية أكاديمية
المؤلفون: Trapp, Christian, Grosu, Anca-Liga, Kirste, Simon, Spohn, Simon, Zamboglou, Constantinos, Schmidt-Hegemann, N.-S.
المصدر: European journal of nuclear medicine and molecular imaging. - (2024) , ISSN: 1619-7089
الإتاحة: https://doi.org/10.1007/s00259-024-06802-xTest
https://freidok.uni-freiburg.de/data/251710Test
